The following findings represent survey responses of medical directors and pharmacy directors (N = 57) from 9 national and many regional health plans from around the country. The survey was conducted during the March 2008 Managed Care Network1 meeting in Orlando, Florida. The percentages shown in the figures represent responses provided by between 49 and 52 of the members who replied to the survey. Additional information can be obtained from Xcenda’s 2008 Oncology Report.2
1. Managed Care Network (MCN) is comprised of 100 medical and pharmacy directors representing more than 150-million covered lives. MCN conducts payer market research and provides strategic guidance to the pharmaceutical industry. In 2007, MCN became a part of Xcenda/AmerisourceBergen Specialty Group (for more information visit http://www.mcnweb.com.).
2. Xcenda/AmerisourceBergen Specialty Group. 2008. Oncology Report. Self-administered v. provider administered: how route of administration in oncology products affects payer coverage and product strategy. http://www.xcenda.com/MediaCenter/OncologyResearch.html. Accessed September 10, 2008.